ML382
CAS No. 1646499-97-9
ML382( —— )
Catalog No. M22112 CAS No. 1646499-97-9
ML382 is a potent and selective MrgX1 positive allosteric modulator(EC50 : 190 nM).ML382 enhances the ability of BAM8-22 to inhibit high-voltage-activated Ca2+ channels and attenuate spinal nociceptive transmission, both BAM8-22 and ML382 effectively attenuated evoked, persistent, and spontaneous pain without causing obvious side effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 44 | In Stock |
|
| 5MG | 39 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 124 | In Stock |
|
| 50MG | 221 | In Stock |
|
| 100MG | 328 | In Stock |
|
| 200MG | 458 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameML382
-
NoteResearch use only, not for human use.
-
Brief DescriptionML382 is a potent and selective MrgX1 positive allosteric modulator(EC50 : 190 nM).ML382 enhances the ability of BAM8-22 to inhibit high-voltage-activated Ca2+ channels and attenuate spinal nociceptive transmission, both BAM8-22 and ML382 effectively attenuated evoked, persistent, and spontaneous pain without causing obvious side effects.
-
DescriptionML382 is a potent and selective MrgX1 positive allosteric modulator(EC50 : 190 nM).ML382 enhances the ability of BAM8-22 to inhibit high-voltage-activated Ca2+ channels and attenuate spinal nociceptive transmission, both BAM8-22 and ML382 effectively attenuated evoked, persistent, and spontaneous pain without causing obvious side effects. Notably, ML382 by itself attenuated both evoked pain hypersensitivity and spontaneous pain in MrgprX1 mice after nerve injury without acquiring coadministration of an exogenous agonist.
-
In VitroIn the absence of ML382, the IC50 for BAM8-22 inhibition of ICa is 0.66 ± 0.05 μM. In the presence of 0.1 μM, 1 μM, 10 μM, and 30 μM ML382, BAM8-22 IC50 is reduced to 0.43 ± 0.02 μM, 0.25 ± 0.02 μM, 0.06 ± 0.01 μM, and 0.08 ± 0.01 μM, respectively. A lower IC50 generally indicates a higher potency; thus, ML382 dose-dependently increases the potency of BAM8–22, further demonstrating that ML382 is a positive allosteric modulator of MRGPRX1.
-
In VivoML382 (5 μM) significantly increases inhibition of ICa by a low concentration of BAM8–22 (0.5 μM) in DRG neurons from MrgprX1 mice. ML382 enhances the inhibition of spinal synaptic transmission by BAM8-22 in MrgprX1 mice. ML382 (25 μM, 125 μM, and 250 μM; 5 μL; i.th.;) dose-dependently attenuates heat hypersensitivity in MrgprX1 mice. ML382 (lumbar puncture injection; 25 μM, 5 μL) leads to a significant increase in postconditioning time spent in the ML382-paired chamber, compared with the preconditioning value. ML382 inhibits nerve injury-induced ongoing pain in MrgprX1 mice.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorMrgX1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1646499-97-9
-
Formula Weight360.42
-
Molecular FormulaC??H??NO?
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (277.45 mM)
-
SMILESCCOc1ccccc1NC(=O)c1ccccc1NS(=O)(=O)C1CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wen W, et al. Discovery and characterization of 2-(cyclopropanesulfonamido)-N-(2-ethoxyphenyl)benzamide, ML382: a potent and selective positive allosteric modulator of MrgX1. ChemMedChem. 2015;10(1):57-61.
molnova catalog
related products
-
AU-15330
AU-15330 is a proteolytic targeting chimera (PROTAC) that simultaneously targets SMARCA4, SMARCA2, and PBRM1 for degradation and exhibits cytotoxicity in H3.3K27M cells but not in H3 wild-type cells.
-
Carbobenzoxyproline
Carbobenzoxyproline is a prolidase inhibitor.
-
CMPF
CMPF is a microtubule protein inhibitor that can be used to study tumors.
Cart
sales@molnova.com